Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 18/20 | 0.54 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | IDH1 | O75874 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL525610 | 1.00 | HSD11B1 (0.54) | HSD11B1CHEK1IDH1 | |
| SCHEMBL10086305 | 0.90 | HSD11B1 (0.52) | HSD11B1IDH1 | |
| SCHEMBL525274 | 0.90 | HSD11B1 (0.52) | HSD11B1IDH1 | |
| SCHEMBL525706 | 0.90 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL10085606 | 0.90 | HSD11B1 (0.57) | HSD11B1 | |
| SCHEMBL10103199 | 0.85 | HTR3E (0.42) | HSD11B1CHEK1IDH1 | |
| SCHEMBL10086314 | 0.85 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL525063 | 0.85 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL525405 | 0.83 | HSD11B1 (0.55) | HSD11B1 | |
| SCHEMBL10085246 | 0.83 | HSD11B1 (0.55) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513430-B2 | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029029-A1 | SUBSTITUTED THIAZOL-2-YLAMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS 11-BETA HSD1 MODULATORS | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885CHEK1 4602/4885IDH1 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.